Yu. A. Danilogorskaya

Yu. A. Danilogorskaya

Auto-generated profile, based on publicly available information

Yu. A. Danilogorskaya

I.M. Sechenov First Moscow Medical University (Sechenov University), Moscow

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2022 in Kardiologiia
Verified
Journal Article
Closed access
PDF file
JSJu. I. Safonova
Ju. I. Safonova
MKMaria Kozhevnikova
Maria Kozhevnikova
YDYu. A. Danilogorskaya
Yu. A. Danilogorskaya
EZE. A. Zheleznykh
E. A. Zheleznykh
III. S. Ilgisonis
I. S. Ilgisonis
YBYuri Belenkov
Yuri Belenkov
Aim      To evaluate the effect of perindopril on the endothelial function and levels of endothelial dysfunction markers in groups of patients with heart failure with preserved (HFpEF) and mid-range (intermediate) left ventricular ejection fraction (HFmrEF). Material and methods  40 patients with HFpEF (n=20) and HFmrEF (n=20) were evaluated. At baseline, parameters of the morpho-functional state of large blood vessels and of microvessels were evaluated with photoplethysmography, and levels of E-selectin and endothelin-1 (ET-1) were measured. The patients were prescribed perindopril, and after 12 months of treatment, photoplethysmographic parameters and endothelial dysfunction markers were determined again. Results After 12 months of the perindopril treatment, improvements in the endothelial function of both large blood vessels and microvessels were noted. The phase shift increased from 10.1 to 10.9 ms in the HFpEF group (р=0.001) and from 8.35 to 9.65 ms in the HFmrEF group (р=0.002). Furthermore, the occlusion index increased from 1.45 to 1.75 in patients with HFpEF (р=0.004) and from 1.5 to 1.75 in patients with HFmrEF (р=0.010). The Е-selectin concentration decreased in both groups, from 57.25 to 42.4 ng/ml (р=0.00008) and from 40.5 to 35.7 ng/ml (р=0.010) in patients with HFpEF and HFmrEF, respectively. The ET-1 concentration decreased from pg/ml (р=0.010) in patients with HFpEF whereas in patients with HFmrEF, there was no significant change in the ET-1 concentration after 12 months of the perindopril treatment. Conclusion      At 12 months, the endothelial function improved and E-selectin and ET-1 levels decreased in patients with HFpEF and HFmrEF.

7 September 2020 in Kardiologiia
Verified
Journal Article
Closed access
PDF file
JSJ. I. Safonova
J. I. Safonova
MKMaria Kozhevnikova
Maria Kozhevnikova
YDYu. A. Danilogorskaya
Yu. A. Danilogorskaya
EZE. A. Zheleznykh
E. A. Zheleznykh
VZV. Y. Zektser
V. Y. Zektser
YBYuri Belenkov
Yuri Belenkov
Aim      To evaluate the effect of 12-month perindopril treatment on structure and function of microvasculature (MV) in patients with chronic heart failure with preserved (HFpEF) and intermediate (HFiEF) left ventricular ejection fraction. Material and methods  30 patients with HFpEF and HFiEF were evaluated. Perindopril at a maximum tolerated dose was administered to all patients for 12 months. Changes in MV structure and function were assessed with photoplethysmography and capillaroscopy prior to the treatment onset and at 12 months, i.e., after completion of the perindopril treatment. Results The 12-month perindopril treatment was associated with improvement of the endothelial function evident as increases in the occlusion index (OI) and the phase shift (PS). OI increased from 1.45 [1.3; 1.6] to 1.8 [1.6; 2.2] (p=0.00004). PS increased from 7.1 ms [4.8; 10.2] to 9.2 ms [6.7; 13.2] (p=0.0003). Stiffness of muscular large blood vessels was decreased. Arterial stiffness index (aSI) decreased from 8.8 [6.6; 11.0] to 7.45 [6.5; 9.4] m /s (р=0.01). The perindopril treatment was associated with increased density of the capillary network at rest (р=0.008) and in tests with venous occlusion (р=0.003) and reactive hyperemia (р=0.0003). Conclusion      The study showed an improvement of endothelial function associated with the 12-month perindopril therapy in patients with HFpEF and HFiEF.

13 July 2021 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
ASAnastasia Shchendrygina
Anastasia Shchendrygina
KZK. A. Zhbanov
K. A. Zhbanov
EPE. V. Privalova
E. V. Privalova
AIAlfiya Oskarovna Iusupova
Alfiya Oskarovna Iusupova
YDYu. A. Danilogorskaya
Yu. A. Danilogorskaya
YBYuri Belenkov
Yuri Belenkov
Heart failure with preserved ejection fraction (HFpEF) is a syndrome associated with high morbidity and mortality rates. Little progress has been in the treatment of this condition since its introduction some 30 years ago. It's accepted that HFpEF is heterogeneous in many ways, ethologically and phenotypically. The underlying mechanisms of the syndrome are not clear. Recently, it has been shown that the diagnostic criteria for HFpEF lacks sensitivity and specificity. Novel treatment approaches, which were developed based on current HFpEF pathophysiological concepts, did not show either clinical or prognostic benefit for patients. Therefore, there is an urgent need to revise current diagnostic approaches and to further investigate the underlying mechanisms. Recently, two novel diagnostic score systems were proposed: H2PEF and HFA-PEFF. Recently, a number of phase II and III randomized control trials have been completed. Here, the authors discuss the potential novel diagnostic approaches to HFpEF and treatment perspectives.

6 February 2020 in Kardiologiia
Verified
Journal Article
Closed access
PDF file
YDYu. A. Danilogorskaya
Yu. A. Danilogorskaya
EZE. A. Zheleznykh
E. A. Zheleznykh
EPE. A. Privalova
E. A. Privalova
YBYuri Belenkov
Yuri Belenkov
ASAnastasia Shchendrygina
Anastasia Shchendrygina
NKN. V. Khabarova
N. V. Khabarova
Objective Investigate the dynamics of morphological and functional markers of vascular remodeling in patients with arterial hypertension (AH), including those with concomitant type 2 diabetes mellitus (DM2), during 12-month administration of perindopril A. Material and Methods The study included patients with grade I-II AH, with and without DM2 (30 and 32 patients, respectively), who underwent outpatient correction of initially ineffective antihypertensive therapy and administration of perindopril A, 10 mg/day. Morphological and functional parameters of vascular remodeling were evaluated in all patients at baseline and at 12 months using photoplethysmography. Stiffness index (SI) and phase shift (PS) were measured in large vessels. Reflection index (RI) and occlusion index (OI) were measured in microvessels. Computed nailfold videocapillaroscopy was used to determine capillary density (CD) at rest (CDr), CD during venous occlusion test (CDvo), and CD during reactive hyperemia test (CDrh). Data are medians [interquartile range]. Results After 12-month administration of perindopril A, the morphological and functional parameters of vascular remodeling in AH patients without DM2 significantly improved at all vascular levels. SI decreased to 9.25 [7.8; 10.93 ] m/s and PS increased to 7.4 [5.6; 9.05] ms. In microvasculature, a statistically significant reduction was observed in RI, 31 [27; 36.5]%, and an increase was observed in OI, which characterizes endothelium function, 1.75 [1.68; 1.9]. Capillary CDr significantly increased to 40.5 [34.93; 46] cap/mm2, as did CDvo and CDrh. At the same time, in the group of patients with AH and DM2, a significant improvement was observed for the large vessels. SI decreased to 9.8 [9.08; 10.58] m/s, and PS increased to 6.95 [5.13; 10.08]. The RI index, reflecting the structural condition of arterioles, significantly decreased to 34 [25.9; 45.53]%, and the OI index, characterizing endothelial function, did not change significantly, 1.4 [1.3; 1.6]. Capillary CDr significantly increased to 31.55 [27.68; 34.7 ] cap/mm2; however, CDvo and CDrh did not change significantly. Renal function improved in both groups. Conclusion Both groups demonstrated improvement of morphological parameters at all levels of the arterial bed. However, patients with AH and concomitant DM2 showed no improvement of the endothelial function of arterioles and capillaries compared to improvement in AH patients without DM2. This reflected the more severe endothelial dysfunction present in AH patients with DM2.

31 January 2022 in Kardiologiia
Verified
Journal Article
Closed access
PDF file
EPE. A. Privalova
E. A. Privalova
YBYuri Belenkov
Yuri Belenkov
YDYu. A. Danilogorskaya
Yu. A. Danilogorskaya
EZE. A. Zheleznykh
E. A. Zheleznykh
MKMaria Kozhevnikova
Maria Kozhevnikova
III. S. Ilgisonis
I. S. Ilgisonis
Оценка динамики уровня сывороточных маркеров ремоделирования сосудистого русла у больных артериальной гипертензией, в том числе в сочетании с сахарным диабетом 2‑го типа, на фоне 12‑месячного лечения периндоприлом А

8 February 2022 in Safety and Risk of Pharmacotherapy
Verified
Journal Article
Open access
PDF file
VAV. V. Arkhipov
V. V. Arkhipov
TKT. S. Kheilo
T. S. Kheilo
EGE. G. Gladysheva
E. G. Gladysheva
YDYu. A. Danilogorskaya
Yu. A. Danilogorskaya
MDM. R. Dzhavatkhanova
M. R. Dzhavatkhanova
ЮДЮ. А. Данилогорская
Ю. А. Данилогорская
Microcirculation dysfunction plays a significant role in the development of post-COVID syndrome caused by SARS-CoV-2. However, there have been no studies on changes in microcirculation parameters during pharmacotherapy in patients with post-COVID syndrome. To date, there are no consensus recommendations for the treatment of post-COVID syndrome in the Russian Federation.The aim of the study was to analyse the pattern of clinical manifestations of post-COVID syndrome and bulbar conjunctival angioscopy (BCA) results in a young patient undergoing treatment after mild COVID-19.Materials and methods: analysis of the clinical case of a patient who was followed up at the Therapeutic Ophthalmology Centre between February and September 2021. BCA was performed in a patient with post-COVID syndrome to compare quantitative and qualitative microcirculation parameters before and after the treatment.Results: the paper summarises clinical observation data on a 23-year-old female patient with post-COVID syndrome with mainly neuropsychiatric manifestations and a microcirculation dysfunction as determined by BCA. The patient received pharmacotherapy with meldonium, ethylmethylhydroxypyridine succinate, and meglumine sodium succinate.Conclusions: the prescribed pharmacotherapy led to a significant improvement in the patient’s condition (regression in neuropsychiatric symptoms) with simultaneous improvement of morphological and functional parameters assessed by BCA, which indicates an improvement in microcirculation processes and supports their role in post-COVID syndrome development. The obtained data suggest that the clinical picture of post-COVID syndrome is directly related to the severity of microcirculation dysfunction in various organs and tissues, and that BCA can be used for diagnosis and assessment of the syndrome’s severity, as well as for assessment of the treatment’s efficacy and safety.